Home › Compare › BTRMF vs ABBV
BTRMF yields 1737.62% · ABBV yields 3.06%● Live data
📍 BTRMF pulled ahead of the other in Year 1
Combined, BTRMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BTRMF + ABBV for your $10,000?
Battery Mineral Resources Corp. engages in acquisition, exploration, and development of battery mineral properties for lithium-ion battery and energy storage sector in Canada, the United States, Chile, and South Korea. It primarily explores for cobalt, gold, copper, lithium, and graphite minerals. The company holds interests in the Cobalt District Exploration project consisting of mineral claims and leases covering an aggregate of 100,674 hectares in Ontario and 1,813 hectares in Quebec. It also holds 100% interests in the Bonanza Project in Idaho and Amargosa Project in Nevada; Geumam and Taehwa projects located in South Korea; and the Punitaqui Mining Complex in the Coquimbo region of Chile. In addition, the company leases and sells padding machine, a backfill separation machine to mainline pipeline, renewables and utility construction, and oilfield pipeline and construction contractors. Battery Mineral Resources Corp. is headquartered in Vancouver, Canada.
Full BTRMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.